Technology Innovations, LLC

Investors in Lumineu, Inc. and Electrohealing Technologies, Inc.
Presenting at the 2016 NanoBusiness Alliance Conference.

An Astonishing Breakthrough in Nanotechnology

“The next revolution in medicine.”

- Richard M. Satava, MD
  former DARPA program manager
Breakthrough Discovery:

Nanowaves™

- We all know that light can be both a wave and a particle.

- However, we did not realize that nanowaves can impact human cells and induce healing outcomes, non-invasively, and transcranially.

- No particles required! No brain barrier to penetrate. No cutting, drilling, infusing. No sepsis.

- As were minimally-invasive technologies when first brought to the clinic: balloon angioplasty, laparoscopy, valves, stents, et al.
Breakthrough Discovery:

News:

- This technology is the next revolution in medicine.

- We have quietly been patenting, licensing and aggregating, while the stoic industry has been asleep.

- Starting with Alzheimer’s and then regenerative medicine, we intend to disrupt the non-competitive world of healthcare.

- Competition will change the pace of innovation, and disrupt the arrogance and aristocracy of Big Pharma and Devices.

- As it has in IT, smartphones, digital photography, and telecom.
Unanticipated Upside Solution to:

ALZHEIMER’S

- Lumineu has a solution working in humans to stop and stabilize Alzheimer’s. Ignored by NIH and the incumbents in industry.

- Clinical evidence of stopping and stabilizing Alzheimer’s and TBI using photobiomodulation, neurofeedback, and transcranial ultrasound.

- A strong international patent thicket has been filed and there are issued patents in hand. We are partnering with offshore entities, as the incumbents are stuck in the old paradigm.
Breakthrough Discovery:

Alzheimer’s

- 60 million people worldwide have dementia
- 40 million of them have Alzheimer’s
- The US military spent $850 million in R&D for TBI, and found photobiomodulation helps repair the damage from TBI, and Alzheimer’s.
- We have spent two years and 7 figures to get to this point of opportunity.
- Lumineu has acquired the IP for this solution, with significant improvements over the prior art. Lumineu has acquired the IP of Noothera, LLC.
- Lumineu.com NooThera.com
PhotoBioModulation

CELLULAR MECHANISMS

NEAR INFRARED LIGHT

MITOCHONDRIUM

NO → ROS → ATP

PKD → IκB → NF-κB → NF-κB

cAMP → Jun/Fos → AP-1

GENE TRANSCRIPTION

High End Summary of Lumineu

• Lumineu is run by a combination of experienced clinicians and industry executives.

• Lumineu’s business model is to control the IP and first demonstrations of efficacy for the non-invasive solution, in combinations, and persuade thought leaders, clinicians and hospitals to adapt it at a rapid scale.

• Lumineu has a large, well capitalized prospect for China, Hong Kong, Taiwan and Singapore interested in an exclusive license for those territories.

• Lumineu has prospects in India, Malaysia, the Middle East, and Europe.

• Lumineu will bring these to market, generate cash flows, and let the US/EU leaders offer bids and proposals, when they recognize the potential they have ignored.
Solution: Effective therapy via telemedicine:

Cloud Based
Analysis / Neural Processing

Lumineu

Photo BioModulation and Neurofeedback

Results Interpreted in Context
Lumineu provides efficacy in new clinical and home therapy solutions.

Objective Neurofeedback with Photobiomodulation
  - Improves Clinical Monitoring & Outcomes

Patient State Confirmation
  - Neurofeedback Doubles Efficacy

Effective Neurological Response
  - Tested in humans to stop degeneration and improve cognition
Dr. Hack served as the Director of the US Army Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), during his 28 year career in the US Army.

One of his major responsibilities was overseeing a portfolio of more than 650 projects directed at traumatic brain injury (TBI).

Prior to joining the Army, Dr. Hack served as the VP of R&D in several medical device ventures.
Management Team = Execution

- Dallas Hack, MD, MPH – CEO. Led the DOD solutions for TBI.
- Joe Kincart – President and COO – 10 years at J&J. Patent Attorney, structured the J&J/IBM JV.
- Stu MacDonald, PE – 10 years at J&J as VP Instrumentation R&D at OCP.
- Trent Nichols, MD – Worked at VA with TBI patients, Has participated in over 50 drug trials. Has personal experience with direct energy.

- SAB
- Mark Kroll, Ph.D. former CTO at St. Jude,
- Bob Crowley, former R&D Director at Boston Scientific (intravascular ultrasound),
- Don Keck, Ph.D. National Medal of Technology Award recipient for optical telecommunications,
- Jason Huang, MD, Chairman of Neurosurgery at Baylor, Scott and White.
- Lucas Koberda, MD Ph.D. – using neurofeedback on epilepsy and dementia patients.
Market Strategy / Customers

Low Cost Home Therapy

$ 20 B Market
Per each 1 million patients
(5 million in US, 40 million, worldwide)

$ 250 M Market

Medical Oversight
Lumineu Pending Patents:

We have issued patents under license.

Plus, Multiple Patent Applications:

SYSTEMS AND METHODS FOR DIRECTED ENERGY CRANIAL THERAPEUTICS

- Pending in U.S. and WIPO
- First to File Patent Position
- US 15/018,701; PCT/US16/17030

SYSTEMS AND METHODS FOR DIRECTED ENERGY THERAPEUTICS

- Pending in U.S. and WIPO
- First to File Patent Position
- US 15/018,723; PCT/US16/17035
$100 million milestone deal

Milestone / Inflection Point

$5 million Match (Germany)

Prep FDA submission

Data Analysis & Algorithm Development

$5 million license with Chinese;

N=160 study

Including home device and clinic

Today

Proof of Concept

Published Data

Completed

$5 million 1st Round

Lumineu Market

$5 million license to China

$5 million license with Chinese;

$100 million milestone deal.

FDA Approval

FDA Submission

$$ Early Revenue

$5 million Match (Germany)

$$ FDA Approval

Milestone / Inflection Point

Milestone / Inflection Point

Milestone / Inflection Point

Development Timeline
Unanticipated Nanowave Solution to:  

CANCER

- Use of millimeter waves (42.5 gigahertz), pioneered in Russia, were tested in the US and showed efficacious in improving chemotherapy.
- Also induced endogenous opioids, reducing pain.
- Further, application of the non-ionizing radiation on melanoma in mice reversed the melanoma in 80% of the mice.
- Upon autopsy, the mice who also had untreated lung cancer tumors (mesothelioma) also reversed, proving remote immune enhancement from the therapy. This was never pursued further, or published.
- Issued and Pending Patents held by Electrohealing Technologies, Inc.
Unanticipated Nanowave Solution to:

CANCER

- We have filed patents and have an issued bioreactor patent to generate a personal vaccine for each patient.

- The technology is held by Electrohealing Technologies, LLC, working on further studies with Wright University and Yale.

- Holds issued and pending patents in cancer, and cardiac rhythm management.
How you can participate:

**Invest, or license:**

- Lumineu, Inc. (Lumineu.com) has a road show this week in NYC and Boston. Being led by Alex Ruckdaeschel – 917-561-3432

- Electrohealing Technologies, Inc. holds and is developing the cancer technology, and has issued and pending patents. Being led by Mike Weiner – 239-603-6446.

- The companies have IP and evidence of organ regeneration using these nanowaves, including kidneys in animals and myocardial tissue in humans, in situ.

- Directed energy also increases pharmaceutical uptake, covered by our IP, and large scale healing suites.
Recognize that:

The next revolution in medicine:

- Has been totally missed by Big Pharma and Medical Devices, Inc.
- Enabling a disruption equal to Microsoft on IT
- And Apple and Google on Microsoft
- We are out for major change and disruption. Will license strong companies who wish to innovate and compete. (Not the old school who do not.)
- Join us, and let’s do well by doing better.
Contact:

The next revolution in medicine:

Michael Weiner

239-603-6446
585-354-3333 (cell)
phasemike@gmail.com
mike@electrohealing.com
Estero, FL (north of Naples)

Bio: www.lifeboat.com/ex/bios.michael.l.weiner